ABSTRACT
ABSTRACT: This retrospective study investigated the effect of ultrasound-guided pulsed radiofrequency (UGPRF) on intercostal neuralgia (ICN) after lung cancer surgery (LCS).This retrospective observational study analyzed the outcome data of UGPRF on ICN in 80 patients with LCS. All those patients were allocated into a treatment group (nâ=â40) and a control group (nâ=â40). All patient data were collected between January 2018 and November 2019. The primary outcome was pain intensity (measured by numerical rating scale, NRS). The secondary outcomes were sleep quality (measured by Pittsburgh Sleep Quality Index, PSQI), anesthetic consumption, and treatment-related adverse events.After treatment, patients in the treatment group showed better outcomes in NRS (Pâ<â.01), PSQI (Pâ<â.01), and anesthetic consumption (Pâ<â.01), than patients in the control group. No treatment-related adverse events were documented in both groups in this study.The results of this study found that UGPRF may benefit patients for pain relief of ICN after LCS.
Subject(s)
Intercostal Nerves , Lung Neoplasms/surgery , Neuralgia/therapy , Pain, Postoperative/therapy , Pneumonectomy/adverse effects , Pulsed Radiofrequency Treatment , Aged , Female , Humans , Male , Middle Aged , Neuralgia/diagnostic imaging , Neuralgia/etiology , Pain, Postoperative/diagnostic imaging , Pain, Postoperative/etiology , Retrospective Studies , Ultrasonography, InterventionalABSTRACT
BACKGROUND: This study aims to systematically assess the effectiveness of high frequency ultrasound (HFUS) on pressure ulcer (PU). METHODS: In this study, PubMed, EMBASE, Cochrane Library, Web of Science, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure will be searched from inception to the present without any language limitations. The primary outcomes include change in ulcer area, and time complete healing. The secondary outcomes consist of proportion of ulcers healed within trial period, quality of life, pain intensity, and adverse events. Cochrane risk of bias tool will be used to assess methodological quality. RevMan 5.3 software (London, UK) will be used to analyze the data. RESULTS: This study will analyze change in ulcer area, time complete healing, proportion of ulcers healed within study period, quality of life, pain intensity, and adverse events on HFUS in patients with PU. CONCLUSION: This study will provide most recent evidence for the effectiveness and safety of HFUS for patients with PU. PROSPERO REGISTRATION NUMBER: PROSPERO CRD42019138177.
